HiDiamond completed nearly RMB 100 million in Pre-A round financing

Recently, HiDiamond successfully closed a Pre-A financing round of nearly 100 million RMB. The round was led by Northern Light Venture Capital, with follow-on investments from Dongwei Fund, Yuanbio Venture Capital, and Luxin Capital. Taihao Fund, an existing angel-round shareholder, also continued to increase its stake in the company.

Proceeds from this round will be primarily used to enrich and advance the preclinical and clinical Proof-of-Concept (POC) studies of our existing pipeline. Additionally, the funds will support the comprehensive rollout of AI and biological organoid platforms in drug R&D and evaluation. We will focus on building core capabilities in target and molecular druggability assessment, molecule and assay design, and multi-dimensional outcome evaluation, thereby effectively improving project initiation and decision-making efficiency, as well as R&D success rates.